Pharmaceutical companies are significant targets for cybersecurity threats due to their possession of sensitive data and valuable intellectual property [1]. This data includes research and development information, clinical trial results, and patient health records, which are highly sought after by malicious actors [1].
What kind of sensitive data do pharmaceutical companies hold?
These companies manage extensive databases containing proprietary research findings, detailed clinical trial data from human subjects, and confidential patient health information. This information is a prime target for industrial espionage, theft, and misuse [1].
How does intellectual property make them a target?
The intellectual property held by pharmaceutical companies, particularly patents on novel drugs and manufacturing processes, represents billions of dollars in potential revenue. Stealing this intellectual property can allow competitors to bypass years of research and development, leading to significant financial losses for the original patent holder [1].
Are there other factors contributing to cybersecurity risks?
While the possession of sensitive data and valuable intellectual property is a primary driver, other industry characteristics can also contribute to cybersecurity vulnerabilities. The use of legacy IT systems, though not explicitly stated as the main reason, can present security gaps if not properly maintained and updated [2]. High employee turnover, also not the primary driver, can create risks if employee access to sensitive systems is not promptly revoked or if departing employees retain unauthorized access or data.
What are the potential consequences of a cybersecurity breach for a pharmaceutical company?
A successful breach can lead to severe consequences, including financial penalties, reputational damage, compromised patient safety, and the loss of competitive advantage through stolen intellectual property [1].